Blog

Home  /  Collaborations   /  PTJA12 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.

PTJA12 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.

EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA12 addresses ‘Glasdegib indicated for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML)’, submitted by Pfizer. We are delighted that HVB and NCPE are authoring this assessment.

We will be issuing an Open Call for Patient Input in due course.